DOI: 10.1055/s-00000071

Seminars in Neurology


Kircik L, Krueger J, Hougeir F , et al.
Incidence, severity, duration and treatment of cutaneous adverse events in the DECIDE study of daclizumab HYP versus intramuscular interferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Poster session presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 7–10, 2015; Barcelona, Spain

Download Bibliographical Data

Search in: